

Study: Dog breed tied more to looks than behavior

AVMA, May 25th 2022



Recent study results suggest a dog's breed is more of a measure of appearance than how a dog will act. The findings, published in the April 29 issue of the journal *Science*, indicate the behaviors attributed to certain dog breeds likely developed over thousands of years predating modern breeds. Those behaviors "are polygenic, environmentally influenced, and found, at varying prevalence, in all breeds," it states. The authors examined survey results from owners of about 18,000 dogs—about half of them purebred—and sequenced DNA from 2,155 of those dogs. The authors found high variability in behavior within dog breeds and breed was almost useless in predicting, for example, how easily a dog would be provoked by frightening, annoying, or uncomfortable stimuli. Breed ancestry was, however, a more accurate predictor of some characteristics, such as a dog's ability to respond to directions and commands, the article states. Yet, biddability, which was the most heritable behavior trait by breed, varied significantly among individual dogs and thus wouldn't be considered a reliable predictor.

Bioiberica HA acid matrix delivers optimised skin benefits

Nutraceutical Business Review, May 19th 2022

An in-vitro human study found Dermal supplementation offered superior effects when compared to standard HA. A study presented at the Experimental Biology Congress (Philadelphia, 2-5 April) concluded Bioiberica's Dermal ingredient, a hyaluronic acid matrix ingredient for skin & beauty, delivers superior results for skin health over standard hyaluronic acid (HA), a popular ingredient in the nutraceutical industry. Comprising three naturally-occurring components, HA (60-75%), glycosaminoglycans, including dermatan and chondroitin sulfate, (≥10%) and collagen (≥5%), the ingredient reportedly offers anti-ageing, regenerative and moisturising properties to help maintain the health and nutrition of skin. To determine the efficacy of Dermal versus standard HA (a widely studied molecule well-recognised for its anti-ageing benefits) the study explored its effects compared to standard HA from fermentation (HA-F) and extraction (HA-E) origins. The in-vitro study found Dermal supplementation offered superior effects when compared to standard HA for inducing the synthesis of type I collagen, cell proliferation of HDF (human dermal fibroblasts) and cell migration of HEK (human epidermal keratinocytes). This indicates the ingredient can bring regenerative activity to the dermis and epidermis layers of the skin, and support the maintenance and functionality of the dermis better than standard HA. "These latest findings build on a growing bank of pre-clinical evidence highlighting the important benefits of Dermal for skin health," said Daniel Martínez Puig, Head of R&D Human Health, Bioiberica. "Previous studies have revealed the ingredient's mechanism of action, ability to be absorbed in the body and safety when taken orally. But now, we can also confirm that Dermal offers greater efficacy compared to standard HA."

Increased dental disease risk for poodle crosses – census

Vet Times, May 25th 2022

Poodle crosses could be at increased risk of dental disease, according to preliminary survey results. Digital services company VisioCare launched the Puppy Tooth Census at the end of March to generate data and insights on dental conditions affecting puppies. The early data shows poodle crosses accounting for 25% of all responses, in line with anecdotal reports that vets are seeing more dental conditions in the dog. Retained deciduous teeth and lingually displaced mandibular canines were reported as the main conditions affecting all puppies.

STUDY

Topical treatment with sphingolipids and glycosaminoglycans for canine atopic dermatitis

BMC Veterinary Research, 2020

Skin barrier dysfunction plays a key role in atopic dermatitis (AD). This impairment is related to altered composition and metabolism of epidermal sphingolipids and a deficiency of ceramides. Glycosaminoglycans (GAGs), and especially hyaluronic acid, could be useful in the management of AD. This study aimed to evaluate the effects of a novel topical treatment consisting of sphingolipids and GAGs extracts in dogs with AD. This formulation is different from previously tested products because the sphingolipid extract contained high amounts of sphingomyelin, a precursor of ceramides, and this has been shown to enhance endogenous synthesis of ceramides and to increase lamellar-related structures in vitro. Thus, it was hypothesized that this formulation could improve clinical disease and skin barrier function in patients with AD. **The clinical benefits reported in the present study after the topical administration of sphingolipids and GAGs, especially on pruritus, confirm the efficacy of such combination. It should be stressed that dogs were not on any other medication, which indicates a remarkable benefit of this topical treatment as a sole therapy.** Study design - This study was designed as a prospective, double-blinded, controlled clinical trial with two parallel arms. Dogs were randomly allocated to the control or the treatment groups, using an assignment of numbers to each dog and blind hat draw. Dogs in the control group did not receive any intervention. Dogs in the treatment group were administered a topical product (Atopivet® Spot-on, Bioiberica S.A.U., Barcelona, Spain). This lotion contains 0.5% of a sphingomyelin-rich sphingolipid extract (Biosfeen®, Bioiberica S.A.U., Barcelona, Spain) and 0.5% of a HA-rich GAGs extract (Dermal®, Bioiberica S.A.U., Barcelona, Spain) as active ingredients. The product was applied topically, twice weekly for 8 weeks.

Atopivet®
ORAL SUSPENSION

Presentation:

Bottle of 120ml

Dose

< 10kg - 2ml,
10 - 20kg - 4ml,
20-30kg - 6ml,
>30kg - 8ml



Canine Atopic
Dermatitis
Management

atopivet®
spot-on

Presentation:

16 spot-ons in a box

Dose

< 15kg - 1/week,
> 15kg - 2/week



Stay connected with

facebook.com/vivaldisanimalhealth | instagram.com/vivaldisanimalhealth | linkedin.com/company/vivaldisanimalhealth

VIVALDIS
Animal Health

Vivaldis Health & Foods Pvt. Ltd.

Office No. 803/804, Clover Hills Plaza, NIBM Road, Pune- 411048, Maharashtra, India.

Help-line No.: +91 7767922244 | Email : info@vivaldis.co.in | Website : www.vivaldis.co.in

1. <http://surl.li/cbqly> | 2. <http://surl.li/cbqlz> | 3. <http://surl.li/cbqma>